Tenofovir (all routes except local)

Hearing loss / Auditory deficit

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5278
R13644		 Torre, 2016 Newborn hearing screening referral (or failed screening) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: Yes Control group: non-TDF (mix or unspecified regimens) Exposed group: TDF (mix or unspecified regimens) Indication: HIV 0.79 [0.40;1.52] -/602   -/- - 602
ref
S5273
R13642		 Celen, 2013 Congenital hearing loss 2nd and/or 3rd trimester retrospective cohort unexposed, sick Adjustment: No Control group: Unexposed, sick Exposed group: TDF (only) Indication: CHB 1.10 [0.02;57.89] C 0/21   0/23 0 21
ref
Total 2 studies 0.80 [0.41;1.54] 0 623
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Torre, 2016Torre, 2016 0.79[0.40; 1.52]-60297%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Celen, 2013Celen, 2013 1.10[0.02; 57.89]0213%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 0.80[0.41; 1.54]-6230.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.80[0.41; 1.54]-6230%NATorre, 2016 Celen, 2013 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.10[0.02; 57.89]-21 -NACelen, 2013 1 exposed to other treatment, sickexposed to other treatment, sick 0.79[0.41; 1.54]-602 -NATorre, 2016 1 Tags Adjustment   - No  - No 1.10[0.02; 57.89]-21 -NACelen, 2013 1   - Yes  - Yes 0.79[0.41; 1.54]-602 -NATorre, 2016 1 Control group   - non-TDF (mix or unspecified regimens)  - non-TDF (mix or unspecified regimens) 0.79[0.41; 1.54]-602 -NATorre, 2016 1   - Unexposed, sick  - Unexposed, sick 1.10[0.02; 57.89]-21 -NACelen, 2013 1 Exposed group   - TDF (mix or unspecified regimens)  - TDF (mix or unspecified regimens) 0.79[0.41; 1.54]-602 -NATorre, 2016 1   - TDF (only)  - TDF (only) 1.10[0.02; 57.89]-21 -NACelen, 2013 1 Indication   - CHB  - CHB 1.10[0.02; 57.89]-21 -NACelen, 2013 1   - HIV  - HIV 0.79[0.41; 1.54]-602 -NATorre, 2016 1 All studiesAll studies 0.80[0.41; 1.54]-6230%NATorre, 2016 Celen, 2013 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.10[0.02; 57.89]-21 -NACelen, 2013 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.61[0.32; 1.19]-97726%NATorre, 2016 Torre, 2016 20.510.01.0